Breast cancer
Conditions
Interventions
Patients receive four cycles of epirubicin (90 mg/m2) and cyclophosphamide (600 mg/m2) every 3 weeks, followed by four cycles of nab-PTX (100 mg/m2) on days 1, 8 and 15 in a 28-day cycle. Fifteen cycl
Sponsors
Tokyo Women's Medical University
Tokyo Women&
#39
s Medical University, Yachiyo Medical Center
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1)Patients with histologically diagnosed invasive breast cancer. 2)Resectable case 3)Category of the T2-4, N0-3, M0. 4)Without previous operation or chemotherapy 5)With measurable lesions 6)ECOG performance status 0-2 7)Adequate organ function 8)Written informed concent
Exclusion criteria
Exclusion criteria: Severe complications history of hypersensitivity reaction for important drug in this study Bilateral breast cancer Inflammatory breast cancer Pregnant or nursing women
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| pathological CR(pCR) rate | — |
Secondary
| Measure | Time frame |
|---|---|
| The breast conserving rate, toxicities, feasibility, overall survival, and relapse-free survival | — |
Countries
Japan
Contacts
Public ContactAkira Hirano
Tokyo Women's Medical University, Medical Center East Department of Breast Surgery
Outcome results
None listed